Navigate Up
Launch the Developer Dashboard
CROI 2012 Network Presentations

CROI 2012 took place from March 5-8, 2012 at the Washington State Convention Center in Seattle, Washington. This is the 19th Conference on Retroviruses and Opportunistic Infections. You can view the conference program by clicking here.

To view network presentations for a particular network, click on the double arrow next to the network in list of networks.

Select
  
SelectedACTG
NormalHANC
NormalHPTN
NormalHVTN
NormalIMPAACT
NormalINSIGHT
NormalMTN
NormalMHRP
 

 CROI 2012 Network Presentations

 
  
ACTG
'Three phases of plasma HIV-1 RNA decay revealed by single copy assay (SCA) inantiretroviral-naïve patients initiating ART with raltegravir (RAL), tenofovir (TDF) and emtricitabine (FTC) (ACTG A5248).'

This is a poster presentation (Abstract L-131) authored by A. Andrade, S. Rosenkranz, A. Cillo, D. Lu, E. Daar, J. Feinberg, S. Reed, E. Acosta, D. Kuritzkes, and J. Mellors.
  
ACTG
'Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption (A5197, NWCS 314).'

This is a poster presentation (Abstract G-106) authored by JA Christensen, JZ Li, H. Wang, J. Spritzler, DR Kuritzkes.
  
ACTG
'Impact of chemotherapy for AIDS-related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy (NWCS 334).'

This is a poster presentation (Abstract L-158) authored by A. Cillo, S. Krishnan, D. McMahon, R. Mitsuyasu, M. Para, and J. Mellors.
  
ACTG
'Correlation between infectious HIV-1 recovery from resting CD4+ memory cells and residual plasma viremia in patients on antiretroviral therapy (ART): results from ACTG A5173. (A5173)'

This is a poster presentation authored by RT Gandhi, R. Bosch, E. Aga, A. Bedison, B. Bastow, J. Schmitz, J. Siliciano, R. Siliciano, J. Eron, and J. Mellors.
  
ACTG
'Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. (A5197)'

This is a poster presentation (Abstract G-102) authored by JZ Li, C. Brumme, M. Lederman, Z. Brumme, H. Wang, J. Spritzler, M. Robertson, M. Carrington, B. Walker, R. Schooley, and DR Kuritzkes.
  
ACTG
'Immune activation in HIV-1 patients experiencing transiently detectable viremia during antiretroviral treatment. (DACS 279)'

This is a poster presentation (Abstract D-267) authored by B. Taiwo, P. Hunt, R. Gandhi, A. Ellingson, M. McKenna, J. Jacobson, and R. Bosch.
  
ACTG
'The association between body composition, soluble and cellular immune activation biomarkers, and bone mineral density in antiretroviral therapy (ART) -naïve HIV-1 infected persons: baseline results of ACTG study A5260s.'

This is  a poster presentation (Abstract O-258) authored by TT Brown, JS Currier, Y. Chen, H. Ribaudo, J. Touw, J. Rothenberg, MP Dube, R. Murphy, JH Stein, and GA McComsey.
  
ACTG
'Genome-wide association study of cervical dysplasia risk in HIV infected women - ACTG DACS 268.'

This is a poster presentation (Abstract U-110) authored by M. Cespedes, R. Holzman, P. McLaren, H. Ostrer, P. de Bakker, and J. Aberg.
  
ACTG
'Progression of atherosclerosis: understanding RAGE (Receptor for Advanced Glycation Endproducts) NWCS 332.'

This is a poster presentation (Abstract O-146) authored by A. Danoff, M. Kendall, J. Currier, T. Kelesidis, A. Schmidt, and J. Aberg.
  
ACTG
'ACTG NWCS 332/A5078 study: biomarkers of microbial translocation and macrophage activation are associated with progression of atherosclerosis in HIV infection. (NWCS 332)'

This is an oral presentation (Abstract O-155) authored by T. Kelesidis, OO Yang, MA Kendal, HN Hodis, and JS Currier.
  
ACTG
'Changes in subcutaneous (SC) fat mitochondrial DNA (mtDNA) and function in antiretroviral therapy (ART)-naïve subjects randomized to abacavir/lamivudine (ABC/3TC) or tenofovir DF/emtricitabine (TDF/FTC) with atazanavir/ritonavir (ATV/r) or efavirenz (EFV): AIDS clinical trials group (ACTG) study A5224s a substudy of A5202. (A5224s) '

This is a poster presentation authored by G. McComsey, E. Daar, M. O'Riordan, A. Collier, L. Kosmiski, J. Santana, C. Fichtenbaum, P. Sax, D. Libutti, and M. Gerschenson.
  
ACTG
'Changes in inflammation and endothelial activation markers in antiretroviral-naïve subjects randomized to abacavir/lamivudine (ABC/3TC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) along with efavirenz (EFV) or atazanavir/ritonavir (ATV/r): AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. (A5224s) '

This is an oral and poster presentation authored by GA McComsey, D. Kitch, ES Daar, C. Tierney, NC Jahed, K. Melbourne, B. Ha, TT Brown, A. Bloom, PE Sax.
  
ACTG
'Tuberculosis associated with neuropsychological and neurological dysfunction in HIV: AIDS clinical trials group study A5199, the international neurological study. (A5199)'

This will be is a poster presentation authored by K. Roberson, H. Jiang, J. Kumwenda, K. Supparatpinyo, S. Evans, T. Campbell, R. Price, J. Hakim, S. Tripathy, and M. Hosseinipour.
  
ACTG
'Ultrasonographic measures of cardiovascular disease risk in a modern cohort of antiretroviral treatment (ART)-naïve individuals with HIV infection: baseline results from ACTG study 5260s'

This is a poster presentation (Abstract O-158) authored by J. Stein, T. Brown, H. Ribaudo, Y. Chen, M. Yan, E. Lauer-Brodell, GA McComsey, M. Dube, H. Hodis, and J. Currier.
  
ACTG
'Effect of sex, race-ethnicity, and NRTIs on atazanavir pharmacokinetics in AIDS clinical trials group study A5202.'

This is a poster presentation (Abstract N-156) authored by C. Venuto, Q. Ma, K. Mollan, C. Tierney, S. Rosenkranz, K. Smith, E. Daar, P. Sax, M. Fischl, A. Collier, and G. Morse.
  
ACTG
'ZOSTAVAX® is generally safe and immunogenic in HIV-Infected adults with CD4 counts > 200 cells/µL virologically suppressed on antiretroviral therapy: results of a phase 2, randomized, double-blind, placebo-controlled trial (A5247).'

This is an oral presentation (Abstract P-118) authored by CA Benson, L. Hua, JW Andersen, HJ Jiang, DR Bozzolo, P. Annunziato, S. Read, R. Pollard, D. Rusin, and J. Lennox.
  
ACTG
'Genome-wide association study of cervical dysplasia risk in HIV infected women - ACTG DACS 268. '

This is a poster presentation (Abstract U-110) authored by M. Cespedes, R. Holzman, P. McLaren, H. Ostrer, P. de Bakker, and J. Aberg.
  
ACTG
'Baseline vitamin D levels do not predict early virological response in patients with HIV/HCV coinfection. (NWCS 330).'

This is an oral and poster presentation (Abstract Q-116) authored by A. Branch, M. Kang, K. Hollabaugh, R. Chung, and M. Glesby.
  
ACTG
'Effect of HCV treatment upon lipid profile and insulin resistance: results from A5178 (SLAM-C) study.'

This is  a poster presentation (Abstract Q-155) authored by AA Butt, T. Umbleja, JW Andersen, RT Chung, and KE Sherman.
  
ACTG
'Nitazoxanide (NTZ) may mitigate the unfavorable association between IL28B genotype and hepatitis C virus (HCV) treatment response to pegylated interferon-based therapy (A5269, NWCS 337).'

This is a poster presentation (Abstract Q-143)authored by A. Luetkemeyer, T. Umbleja, V. Amorosa, B. Abu Dayyeh, R. Chung, M. Kang, M. Bardin, DW Haas, P. Tebas, and M. Peters.
  
ACTG
'Pilot study of pioglitazone prior to HCV re-treatment in HIV/HCV genotype 1-infected subjects with insulin resistance and prior nonresponse to peginterferon (PEG) and ribavirin (R) therapy (ACTG 5239).'

This will be a poster presentation authored by K. Marks, D. Kitch, R. Chung, J. Andersen, C. Hadigan, P. Tien, B. Alston-Smith, and M. Glesby.
  
ACTG
'Anticipating the complications of early HIV-TB co-treatment: Severity and timing of paradoxical tuberculosis immune reconstitution syndrome(TB IRIS) in a 48-week multicenter randomized trial of immediate (within 2 weeks) vs. early (between 8-12 weeks) antiretroviral therapy (ART) in patients with CD4+ <250 cells/mm3 starting TB treatment (A5221 STRIDE study).'

This is an oral presentation (Abstract P-125) authored by A. Luetkemeyer, M. Kendall, M. Nyirenda, X. Wu, P. Ive, J. Andersen, S. Swindells, I. Sanne, D. Havlir, and J. Kumwenda.
  
ACTG
'Sensitivity and specificity of mycobacterium tuberculosis screening and diagnostics in HIV-infected individuals: ACTG study 5253.'

This is an oral and poster presentation (Abstract P-171) authored by S. Swindells, L. Komarow, S. Tripathy, S. Gengiah, J. Achkar, R. MacGregor, B. Putnam, K. Buck, R. Allen, and D. Katzenstein.
  
ACTG
'Pre-HAART initiation soluble CD14 levels vary by country, race, and sex (NWCS 319).'

This is a poster presentation (Abstract D-192) authored by A. Balagopal, V. Franco, L. Smeaton, T. Campbell, N. Kumarasamy, J. Hakim, R. Mitsuyasu, R. Bollinger, D. Thomas, and A. Gupta.
  
ACTG
'The risk of virologic failure associated with low frequency nevirapine (NVP)-resistant variants in women initiating NVP-containing ART varies depending on the history of exposure to single dose nevirapine (sdNVP): OCTANE/ACTG 5208.'

This is an oral presentation (Abstract M-141) authored by V. Boltz, Y. Bao, S. Lockman, E. Halvas, J. McIntyre, R. Schooley, M. Hughes, J. Coffin, and J. Mellors.
  
ACTG
'Sex association with antiretroviral efficacy outcomes in a prospective randomized clinical trial of antiretroviral therapy in diverse multinational settings: the ACTG PEARLS study (A5175).'

This is an oral presentation (Abstract U-107) authored by C. Firnhaber, L. Smeaton, B. Grinsztejn, Y. Chen, U. Lalloo, S. Faesen, W. Sananeka, J. Lama, A. Rana, and T. Campbell.
  
ACTG
'Women with HIV-1 subtype C have higher genital tract HIV-1 RNA before antiretroviral therapy and all women are less likely to durably suppress genital tract HIV-1 RNA than men while on treatment (A5185s).'

This is an oral and poster presentation (Abstract U-136) authored by S. Fiscus, S. Cu-Uvin, A. Eshete, M. Hughes, M. Hosseinipour, B. Grinsztejn, S. Badal-Faesen, J. Dragavon, R. Coombs, and T. Campbell
  
ACTG
'Genome-wide association study (GWAS) of plasma efavirenz pharmacokinetics in AIDS clinical trials group (ACTG) protocols. (NWCS 275)'

This is an oral and poster presentation (Abstract I-124)authored by B. Grady, M. Ritchie, E. Acosta, G. Morse, E. Daar, R. Gulick, G. Robbins, P. McLaren, and D. Haas.
  
ACTG
'Vitamin D insufficiency (VDI) is independently associated with HIV disease progression and death after combination antiretroviral therapy (cART) initiation in resource-limited settings (RLS) (NWCS 319).'

This is a poster presentation (Abstract O-156) authored by F. Yavers, L. Smeaton, B. Detrick, T. Campbell, R. Bollinger, J. Hakim, N. Kumarasamy, A. Andrade, J. Lama, and A. Gupta.
  
ACTG
'Association of HCV/HIV co-infection with immunovirologic responses to and toxicity of antiretroviral therapy (ART) in treatment naïve HIV-infected subjects enrolled in AIDS clinical trials group (ACTG) randomized clinical trials. (DACS 281)'

This is a poster presentation (Abstract Q-194) authored by L. Hua, C. Tierney, J. Andersen, K. Hollabaugh, M. Glesby, and E. Daar.
Network 
Title 
Description 
Link 
1 - 30Next
Digg Delicious Facebook Newsvine Reddit StumbleUpon Twitter Email Link

share:

SiteMap

sitemap:

© HIV/AIDS Network Coordination